Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Martin Reck(German Center for Lung Research), Christian Manegold(Ontario Institute for Cancer Research), Rodryg Ramlau(Poznan University of Medical Sciences), Venice Archer(AstraZeneca (United Kingdom)), N. Moore(Roche (Switzerland)), Vera Gorbounova(Russian Cancer Research Center NN Blokhin), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Vera Hirsh(Taipei Veterans General Hospital), Petr Zatloukal(Heidelberg University), J. Mezger(Heidelberg University), Natasha B. Leighl(Princess Margaret Cancer Centre)
Cited by 1,511
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k